Abstract: Heart failure with preserved ejection fraction (HFpEF) is a serious threat to human health and a complex clinical syndrome, accounting for about half of all heart failure. With the development of the aging population, the incidence of heart failure with preserved ejection fraction (HFpEF) is increasing year by year, and the mortality rate is comparable to that of heart failure with reduced ejection fraction (HFrEF). Although traditional drug treatment can reduce the rehospitalization rate and mortality rate of HFrEF patients, it cannot effectively improve the prognosis of HFpEF patients. At present, there is no unified understanding of the pathogenesis, diagnosis, treatment and other aspects of HFpEF. In addition, there are limitations in the understanding of HFpEF by clinicians, which makes HFpEF a social public problem and major challenge in the field of cardiovascular prevention and treatment. In order to understand the pathological mechanism and diagnosis and treatment of heart